Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
MOTS-c vs SS-31 (Elamipretide)
An educational, source-based comparison of MOTS-c and SS-31 (Elamipretide) — how each peptide works, what it's researched for, and what to know before going deeper.
A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Research suggests it activates AMPK, enhances insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress — positioning it as a candidate mitochondrial-nuclear signaling peptide.
- Insulin sensitivity
- Exercise capacity and mitochondrial biogenesis
- Age-related metabolic decline
- Obesity models
- • Early-stage research; no approved human therapeutic use.
- • Long-term effects unknown.
Cardiolipin-targeting peptide studied for mitochondrial dysfunction.
A tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure, preserving electron transport efficiency, and reducing reactive oxygen species production.
- Heart failure with preserved ejection fraction
- Primary mitochondrial myopathy
- Age-related muscle dysfunction
- Dry AMD (ophthalmology)
- • Investigational; not FDA-approved.
- • Injection-site reactions are common in trials.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| MOTS-c | The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis | Cell Metabolism | 2015 | Foundational paper establishing AMPK-dependent metabolic effects. |
| MOTS-c | MOTS-c levels decline with age | Aging | 2018 | Circulating MOTS-c associated with age-related metabolic phenotypes. |
| SS-31 (Elamipretide) | Elamipretide in primary mitochondrial myopathy (MMPOWER-3) | Neurology | 2020 | Did not meet primary endpoints but showed signals in subgroup analyses. |
Side-effect & safety grid
- Early-stage research; no approved human therapeutic use.
- Long-term effects unknown.
- Investigational; not FDA-approved.
- Injection-site reactions are common in trials.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
MOTS-c vs SS-31 (Elamipretide) — Key differences
- Class: MOTS-c is classified as Mitochondrial · Metabolic, while SS-31 (Elamipretide) is Mitochondrial.
- Primary research focus: MOTS-c — insulin sensitivity; SS-31 (Elamipretide) — heart failure with preserved ejection fraction.
- Tag: Longevity vs Mitochondrial.